A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (MEDI8897 Ph2b)

MedImmune logo

MedImmune

Status and phase

Completed
Phase 2

Conditions

Respiratory Syncytial Virus Infections

Treatments

Drug: Placebo
Drug: MEDI8897

Study type

Interventional

Funder types

Industry

Identifiers

NCT02878330
D5290C00003

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering their first Respiratory Syncytial Virus (RSV) season.

Full description

This pivotal Phase 2b study will determine if MEDI8897 will be efficacious in reducing medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy preterm infants entering their first RSV season. The population to be enrolled is healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days GA who would not receive RSV prophylaxis. A total of 1500 infants will be randomized 2:1 to receive either MEDI8897 or placebo. Participants will be followed for 360 days after dosing. Enrollment is planned at approximately 197 sites across the USA, Canada, Europe, and the Southern Hemisphere.

Enrollment

1,453 patients

Sex

All

Ages

Under 365 days old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.
  • Infants who are entering their first full RSV season at the time of screening.

Key Exclusion Criteria:

  • Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab.
  • Any fever (>= 100.4°F [>= 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization.
  • Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization.
  • Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection.
  • Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

1,453 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
Treatment:
Drug: Placebo
MEDI8897 50 mg
Experimental group
Description:
Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
Treatment:
Drug: MEDI8897

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems